Alkermes plc. Files 8-K: Director/Officer Changes & Shareholder Votes

Ticker: ALKS · Form: 8-K · Filed: 2025-05-21T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, officer-changes, shareholder-vote

Related Tickers: ALKS

TL;DR

Alkermes 8-K: Board shakeup, new execs, and shareholder votes on tap.

AI Summary

Alkermes plc. filed an 8-K on May 21, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also covers the submission of matters to a vote of security holders and includes financial statements and exhibits.

Why It Matters

This filing provides crucial updates on Alkermes' corporate governance and potential shareholder decisions, which can impact investor confidence and strategic direction.

Risk Assessment

Risk Level: low — The filing is routine corporate disclosure and does not indicate any immediate financial distress or significant negative events.

Key Players & Entities

FAQ

What specific director or officer positions were affected by the changes reported in this 8-K?

The filing indicates changes related to the 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers,' but the specific names and positions are not detailed in the provided excerpt.

Were there any specific matters submitted to a vote of security holders mentioned in the filing?

Yes, the filing explicitly states 'Submission of Matters to a Vote of Security Holders' as an item covered.

What type of financial statements are included as exhibits in this filing?

The filing lists 'Financial Statements and Exhibits' but does not specify the exact nature or period of these statements in the provided text.

What is Alkermes plc.'s fiscal year end?

Alkermes plc.'s fiscal year end is December 31 (1231).

What is the Commission File Number for Alkermes plc.?

The Commission File Number for Alkermes plc. is 001-35299.

From the Filing

0000950170-25-075783.txt : 20250521 0000950170-25-075783.hdr.sgml : 20250521 20250521161515 ACCESSION NUMBER: 0000950170-25-075783 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20250521 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250521 DATE AS OF CHANGE: 20250521 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alkermes plc. CENTRAL INDEX KEY: 0001520262 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 981007018 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35299 FILM NUMBER: 25973322 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 BUSINESS PHONE: 00-353-1-772-8000 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: ANTLER SCIENCE TWO PLC DATE OF NAME CHANGE: 20110804 FORMER COMPANY: FORMER CONFORMED NAME: Antler Science Two Ltd DATE OF NAME CHANGE: 20110509 8-K 1 alks-20250521.htm 8-K 8-K 0001520262 false Alkermes plc. 0001520262 2025-05-21 2025-05-21     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 21, 2025 ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter)   Ireland   001-35299   98-1007018 (State or other jurisdiction   (Commission   (IRS Employer of incorporation)   File Number)   Identification No.)             Connaught House , 1 Burlington Road Dublin 4 , Ireland D04 C5Y6 (Address of principal executive offices)   Registrant's telephone number, including area code: + 353 - 1-772-8000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)       ☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)       ☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))       ☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))     Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Ordinary shares, $0.01 par value   ALKS   Nasdaq Global Select Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).       Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐         Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 21, 2025, at the 2025 annual general meeting of shareholders (the “Annual Meeting”) of Alker

View on Read The Filing